Sun Pharma has released its September 2026 investor presentation, highlighting a solid fiscal year with revenue of Rs 58,200 crore and a 16.1% increase in EBITDA to Rs 17,731.4 crore. The company maintains a strong global footprint, with innovative medicines now accounting for 22% of total sales. With a leadership position in India and consistent growth in the US, Sun Pharma continues its pivot toward a specialty-focused global model. Shareholders are tracking the performance of the 'Ilumya' franchise and the progress of the R&D pipeline.
Sun Pharma FY26 Financial Results and Strategic Outlook
Revenue grew to Rs 58,200 crore in FY26, up 11.9% YoY; EBITDA rose 16.1% to Rs 17,731.4 crore.
Reader Takeaway: Strong growth in innovative medicines and India market leadership offset rising R&D investments and operational costs.
What just happened
Sun Pharma has updated investors on its FY26 performance and Q1 FY27 results. The company achieved a notable 11.9% increase in annual sales, reaching Rs 58,200 crore. Operating efficiency remained high, with an EBITDA margin of 30.3%. For Q1 FY27, the company sustained momentum with a 10.1% YoY revenue growth to Rs 15,183.6 crore and an adjusted net profit of Rs 3,089.4 crore.
Why this matters
Sun Pharma is successfully transitioning from a pure-play generics firm to a global specialty powerhouse. The 'Innovative Medicines' segment is the standout performer, growing from just 7.3% of sales in FY18 to 22% by FY26. Flagship specialty product 'Ilumya' reached US$ 796 million in sales, serving as a critical pillar for the company’s US formulations business.
Segment Performance
India formulations remain the anchor of the company, contributing 33% of revenue (Rs 19,290.4 crore), followed by US formulations at 29% (Rs 16,824.2 crore). Emerging markets and the Rest of the World (RoW) segments contributed 19% and 15% respectively, highlighting a well-diversified geographical risk profile.
What changes now
Management continues to prioritize R&D, allocating approximately 6.1% of sales to innovation. The current pipeline features five New Active Substances in various development stages. With a field force of 16,000 in India alone, the company is doubling down on its domestic market leadership where it currently holds an 8.5% market share.
Risks to watch
Key risks include the high competitive intensity in the US generics space and the execution risk associated with bringing new innovative substances to market. Additionally, ongoing regulatory oversight across its 40 global manufacturing facilities requires sustained compliance efforts.
Context metrics
Sun Pharma currently derives 33% of its revenue from India and 29% from the US. R&D spending to date has hit approximately Rs 34,500 crore. ESG initiatives have seen 43% of total energy needs met through renewable sources.